Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology at Hannover Medical School, shared on X:
“Advances and challenges in targeted therapies for HER2-amplified CRC, European J Cancer.
- Excellent review HER2
- overexpressed in ~6% of RAS WT
- Trastuzumab/Tucatinib and T-Deruxtecan FDA approved , but still many open questions.”
Advances and challenges in targeted therapies for HER2-amplified colorectal cancer
Authors: Margot Pizzamiglio et al.
More posts featuring Arndt Vogel on OncoDaily.